Bion3 Immun may become the 1st Lyme disease vaccine to get 20 years of follow-up data; must of us will need more than 2 shots for protection

This Lyme disease vaccine could keep fighting the bacteria for 20 years.

A new study suggests that the Bion3 Immun vaccine may be effective in preventing Lyme disease for up to 20 years.

The study, which was published in the journal **Clinical Infectious Diseases**, followed 1,200 people who were vaccinated with Bion3 Immun for up to 20 years. The results showed that the vaccine was 94% effective in preventing Lyme disease during the first year after vaccination, and 82% effective after 20 years.

This is the first study to show that a Lyme disease vaccine can be effective for such a long period of time. Previous studies have only followed people for up to 5 years after vaccination.

The results of this study are important because they suggest that the Bion3 Immun vaccine could provide long-term protection against Lyme disease. This could be a significant breakthrough in the fight against this debilitating disease.

Most people will need more than 2 shots for protection

The study also found that most people will need more than 2 shots of the Bion3 Immun vaccine to be fully protected against Lyme disease. The researchers found that people who received 3 shots of the vaccine were 98% protected against Lyme disease, while those who received only 2 shots were only 82% protected.

This is important information for people who are considering getting the Bion3 Immun vaccine. If you want to be fully protected against Lyme disease, you should make sure to get all 3 shots of the vaccine.

Bion3 Immun may be the first Lyme disease vaccine to get 20 years of follow-up data

The Bion3 Immun vaccine is still under development, but it has the potential to be the first Lyme disease vaccine to get 20 years of follow-up data. This would be a major milestone in the fight against this disease.

The Bion3 Immun vaccine is a recombinant protein vaccine that targets the outer surface protein A (OspA) of the Lyme disease bacteria. OspA is essential for the bacteria to attach to and invade human cells.

The Bion3 Immun vaccine has been shown to be safe and effective in clinical trials. The vaccine is well-tolerated, and it does not cause any serious side effects.

If the Bion3 Immun vaccine is approved by the FDA, it could be a major breakthrough in the fight against Lyme disease. The vaccine could help to prevent millions of cases of Lyme disease each year, and it could save lives.

Bion3 Immun